Bisphosphonates Inhibit the Growth ofTrypanosomabrucei,Trypanosomacruzi,Leishmaniadonovani,Toxoplasmagondii, andPlasmodiumfalciparum: A Potential Route to Chemotherapy

Authors:
  • JGJoshua S. Grimley
    Joshua S. Grimley
  • JLJared C. Lewis
    Jared C. Lewis
  • HHHuel T. Heath
    Huel T. Heath
  • BBBrian N. Bailey
    Brian N. Bailey
  • HKHoward Kendrick
    Howard Kendrick
  • VYVanessa Yardley
    Vanessa Yardley
  • ACAura Caldera
    Aura Caldera
  • RLRenee Lira
    Renee Lira
  • JUJulio A. Urbina
    Julio A. Urbina
  • SMSilvia N. J. Moreno
    Silvia N. J. Moreno
  • RDRoberto Docampo
    Roberto Docampo

Abstract
We have investigated the effects in vitro of a series of bisphosphonates on the proliferation of Trypanosoma cruzi, Trypanosoma brucei rhodesiense, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum. The results show that nitrogen-containing bisphosphonates of the type used in bone resorption therapy have significant activity against parasites, with the aromatic species having in some cases nanomolar or low-micromolar IC50 activity values against parasite replication (e.g. o-risedronate, IC50 = 220 nM for T. brucei rhodesiense; risedronate, IC50 = 490 nM for T. gondii). In T. cruzi, the nitrogen-containing bisphosphonate risedronate is shown to inhibit sterol biosynthesis at a pre-squalene level, most likely by inhibiting farnesylpyrophosphate synthase. Bisphosphonates therefore appear to have potential in treating parasitic protozoan diseases.

This publication has 21 references indexed in Scilit: